Ranbaxy Settles With FDA, Sets Aside $500M For DOJ Probe
The Indian drugmaker said it had signed a consent decree with the FDA and agreed to strengthen procedures and policies regarding data integrity and to comply with good manufacturing practices. The settlement is subject to the District of Maryland's approval, according to Ranbaxy.
"We are pleased to have resolved this...
To view the full article, register now.